Course 0 · Lesson 2 · Members
Approval, compounding, and research use only
Why those labels are different objects — not interchangeable permissions.
18+ · No peptide sales · No medical advice
1. Cold open
People treat these three sentences as synonyms. They are not.
“This is approved.” “This was compounded.” “This is labeled research use only.”
Each names a different regulatory object. Permission does not transfer from one to the others. This lesson is education about those objects. It is not legal advice, not medical advice, and not a how-to for preparing or obtaining anything.
2. Object A — Approval
Under the U.S. framework taught here, human prescription drugs are generally marketed after FDA review of an application. Approval is a decision about a specific finished drug product for labeled conditions of use in defined populations. It is not a blanket clearance of a chemical name.
What travels with approval is that product–use–population–label set. What does not travel: other uses, other preparations, other populations, or a similarly named analog.
This is the same habit as Lesson 1’s Approved indication grade. Off-label discussion presupposes an FDA-approved drug product used for an unapproved indication, population, or other unlabeled use. That is not the same object as marketing or using a product that lacks an approved application.
Primary anchors: FDA New Drug Application (NDA); FDA Abbreviated New Drug Application (ANDA); FDA on unapproved use of approved drugs (“off label”).
3. Object B — Compounding
Human drug compounding under the FD&C Act is a different pathway from an approved finished drug product. Section 503A covers certain pharmacy and physician compounding for individual patients. Section 503B covers FDA-registered outsourcing facilities. When statutory conditions are met, those pathways can qualify for limited exemptions from some FD&C Act requirements. A compounded preparation is still not an FDA-approved finished drug product.
Teaching point only: compounded preparation ≠ approved product identity. This lesson does not teach how to compound, how to prepare a vial, or how to order.
Bulk-substance policy and Category tables change. FDA’s January 2025 interim guidances end new categorization into Categories 1/2/3 for nominations on or after the guidance publication date, while describing how previously Category 1 substances may remain in scope until a final list determination. Substances FDA identifies as presenting significant safety risks sit outside Category 1 interim policy. As of Sep 2026, read the live tables — do not freeze a badge from memory.
Shortage status also changes. FDA publishes rolling statements on compounding during GLP-1 shortage and after shortage resolution. As of Sep 2026, use FDA’s live clarification page and the Drug Shortages Database rather than a forum summary.
Primary anchors: FDA FD&C Act provisions that apply to human drug compounding; Bulk drug substances used in compounding; Certain bulk drug substances that may present significant safety risks (as of Sep 2026); FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize (as of Sep 2026); Drug Shortages Database.
4. Object C — Research-use-only labeling
In the in vitro diagnostic (IVD) context, 21 CFR 809.10 addresses labeling for products in the laboratory research phase of development. FDA’s longstanding RUO guidance describes expected labeling such as “For Research Use Only. Not for use in diagnostic procedures.”
What the sources support: RUO labeling is a distribution and intended-use posture for that IVD research-phase setting. It is not FDA approval for clinical diagnostic use, and it is not human-use drug approval.
What this lesson does not claim: that every consumer “not for human consumption” sticker is the same legal object as 21 CFR 809.10(c), or that an RUO phrase is “almost approved,” or that it grants a human-use plan. Keep the label generic. Never illustrate with a shop, domain, or catalog.
Primary anchors: 21 CFR 809.10 (govinfo); FDA guidance on distribution of IVD products labeled for research use only or investigational use only.
5. Substitution table
| People say | Object is actually |
|---|---|
| “Approved — so any use is covered.” | Approval covers a specific product–use–population–label set. |
| “Compounded — same as the approved product.” | Compounding pathway ≠ approved finished drug product identity. |
| “Research use only — almost approved.” | RUO labeling (as cited) is not human-use approval. |
| “Approved for something — approved for this.” | Indication does not travel to another use or preparation. |
| “Discussed for this — established for this.” | Discussion is not an approved indication. |
Equal seriousness. No traffic light. No permission transfer across rows.
6. Status drawer preview
On a compound page, Status holds regulatory posture. Live pages show it as the header status badge. It does not rewrite Evidence snapshot. It does not certify Reported experiences. Lesson 3 opens the three drawers as a reading method.
7. Questions to take
- 1. What exact product, use, population, and label are being named?
- 2. Is this an FDA-approved finished drug product, a compounded preparation, or a research-use-only labeling claim — and which source says so?
- 3. If something is approved, is this that labeled indication?
- 4. What permission does not transfer to another use, preparation, or population?
- 5. Am I reading Status, or am I letting a badge rewrite a paper or a story?
- 6. What would I ask a licensed clinician about this label — without asking the site for a plan?
If a sentence answers by telling you what to use, how much, how often, how to prepare it, or where to get it, it has left the lesson.
8. Close
Close: Lesson 3 opens the three drawers — Evidence, Status, Experience — as a reading method. This lesson has one job: keep approval, compounding, and research-use-only labeling apart.
CTA after the lesson: Open the library · Continue Course 0 · Guidelines
Self-check
Ungraded. Reveal each answer after you attempt the question. No certificate.
1. Approval is best described as…
Answer: A decision about a specific product–use–population–label set — not a general clearance of a molecule.
2. True/False — If a medicine is approved for indication A, that approval automatically covers use B and any similarly named preparation.
Answer: False.
3. Research-use-only labeling means the material is approved for human use.
Answer: False. RUO labeling, as cited in this lesson, is not human-use approval and not a plan.
4. Label these three statements (Approval / Compounding object / RUO labeling / None — plan language): (a) “This finished drug product is approved for indication A in population P.” (b) “This preparation was made under a compounding pathway, not as that approved finished product.” (c) “Start taking this — here is how much.”
Answer: (a) Approval (b) Compounding object (c) None — plan language; does not belong in Course 0.
5. Which library layer should hold regulatory posture?
Answer: Status (header status badge on live pages; fully taught with the other drawers in Lesson 3).
Log in or join to track your progress.Self-check is open to all. Progress tracking needs an account.